Importantly, a case report of mutational activation involving the CCNG1 promoter was recently identified in a breast cancer patient suffering (subsequently) from chemotherapy-related acute myeloid leukemia—which suggested overexpression of the cyclin G1/Cdk2/c-Myc as drivers, while recognizing DeltaRex-G as a prospective and rational therapy in myeloid tumors with typically pore prognosis (Xiao et al., 2020). The gene discussed is CDK2; the disease is myeloid neoplasm.